Variation in Patients' Hospice Costs
We obtained patient-level cost data from one hospice to explore variation in hospice costs across patients. We found that average per day costs decreased as duration of hospice stay increased. Costs per day were lower for nursing home residents than nonresidents. We identify possible alterations to the Medicare per diem payment system that could address these issues, including higher per diems for the first and last days and an adjuster for nursing home residence. However, replicating these results using data from a broader, more representative sample of hospices is needed before making changes to the per diem system.
The Medicare hospice benefit was created by the Tax Equity and Fiscal Responsibility Act of 1982. Although initially used by a relatively low proportion of Medicare beneficiaries after its 1983 implementation, use of the benefit has expanded rapidly over the past several years (MedPAC 2004) . By 2002, 25% of Medicare decedents in the fee-for-service program and 34% in managed care used hospice before they died (MedPAC 2004) . The Medicare hospice benefit reflects the prevailing treatment model for cancer care at the time of the benefit's implementation, focusing on the provision of nursing and supportive care. Despite changes in palliative care technology (for example, new pain medications and durable medical equipment) and the hospice patient population (patients with non-cancer diagnoses now represent almost half of Medicare hospice users [MedPAC 2002] ), the Medicare hospice payment system has remained largely unchanged since the early 1980s-an allinclusive per diem rate for care related to the patient's terminal illness. In contrast, Medicare has moved to prospective, per case payment systems for a variety of services (e.g., hospital care, rehabilitation care, longterm hospital care) over the past two decades, and all of these systems adjust prospective payments on the basis of the case mix of patients and account for outliers.
Neither adjustment currently is made to hospice per diem payments.
While use of hospice has increased, the duration of stays among hospice users has decreased over time. In the Medicare hospice demonstration project conducted from 1980 to 1982, mean duration of stays was 70 days; by 2001, mean duration had dropped to 50 days for the Medicare program (U.S GAO 2004) . Hospice administrators have argued that reductions in duration of stays have made it difficult to average the relatively higher-cost days at the beginning and end of a stay with the relatively lower-cost days in the middle of a stay, resulting in budget shortfalls in some cases (Huskamp et al. 2001) .
There is also evidence of access problems for patients with particularly high-cost palliative care needs (Lorenz et al. 2004; Huskamp et al. 2001) . For example, some hospices do not admit patients receiving high-cost palliative chemotherapy or discharge them so they can receive such care in other settings (Huskamp et al. 2001) .
In 2002, the Medicare Payment Advisory Commission (MedPAC) recommended that hospice rates be evaluated ''to ensure they are consistent with the costs of providing appropriate care'' and that differences in the care received by hospice patients and their resource needs be studied to explore case-mix adjustment or a high-cost outlier policy (MedPAC 2002) . Prospective payment without such adjustments can create incentives for providers to avoid high-cost patients since the provider receives the same payment regardless of the costs incurred in treating a particular patient. This approach to payment also can have negative financial consequences for hospice providers that do not engage in selection behavior if a hospice happens to attract a disproportionate share of high-cost patients at random or because of selection behavior by other local hospices. Adjusting for certain patient characteristics associated with high resource use or employing an outlier payment system to provide additional payment for particularly high-cost cases can lessen the consequences of attracting a disproportionately high-cost pool of enrollees, and thus temper incentives for selection behavior. A barrier to conducting the evaluation recommended by MedPAC has been the lack of person-level utilization and cost data.
In 2004, the U.S. Government Accountability Office (GAO) examined patient-level data from one large for-profit hospice on the types of visits provided to all hospice users (no patient-level cost data were available) and found that the number of patient visits provided by the hospice was higher at the beginning and end of a hospice stay (GAO 2004) . The June 2006 MedPAC report summarized results from a commissioned study by Buntin that also used visit data from a large for-profit hospice (MedPAC 2006) . Like the GAO, she found that patients received more visits at the beginning and end of a stay. She also found that potential case-mix adjusters like diagnoses and demographic information added little explanatory power to models predicting imputed staffing costs of direct patient care.
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To our knowledge, there are no studies of the variation in total hospice costs, including the costs of palliative care medications, durable medical equipment (DME), supplies, and palliative therapies (e.g., palliative radiation), that use patient-level data. Given rising costs for some of these items, data on all hospice costs are necessary to examine the appropriateness of the current per diem payment system. We use a data set that includes cost information for all goods and services provided to patients in one hospice to explore variation in costs across hospice patients, and we consider adjustments to the Medicare per diem payment methodology to address this variation. As described subsequently, the hospice we studied serves a patient population that is similar to the overall population of hospice users nationwide with respect to several demographic and clinical characteristics. As the first study to use detailed patient-level data on total hospice costs to explore cost variation across patients, this analysis provides important insights about the appropriateness of the Medicare per diem payment system.
Medicare Hospice Payment
Medicare is the dominant payer for hospice care; in 2000, almost 80% of all hospice discharges had Medicare as the primary payer (NCHS 2003) . For a person to be eligible for the Medicare hospice benefit, a physician must certify that the patient has a prognosis of six months or less, and the patient must forego coverage of curative treatment for the terminal illness. For hospices to be certified by Medicare, they must cover the following services: skilled nursing care; medical social services; physician services; patient counseling; short-term inpatient care; DME; medical supplies; drugs and biologicals for pain and symptom management; home health aide services; physical, occupational, and speech therapy; inpatient respite care; and family bereavement counseling. Although Medicare now offers prescription drug coverage through Part D, the hospice benefit is responsible for medications for palliative care of the terminal illness.
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The hospice benefit has four payment categories: 1) routine home care (at $135.11/ day in FY 2008); 2) continuous home care, intended only for patients in crisis to enable them to remain living in the home (at $32.86/ hour or $788.55/day); 3) general inpatient care (at $601.02/day); and 4) inpatient respite care (at $139.76/day). Although these four categories represent a crude form of case-mix adjustment, 96% of hospice days paid for by Medicare are for routine home care, and hospice administrators and others report considerable variation in costs across hospice days paid for using a given category of payment.
There is no separate payment rate for patients who receive hospice care while residing in nursing homes, although a 1997 study by the Office of the Inspector General (OIG) of the Department of Health and Human Services found that nursing home residents received nearly 46% fewer nursing and aide services from hospice staff than hospice patients living at home (OIG 1997) . For nursing home hospice patients dually eligible for Medicare and Medicaid, Medicare pays the hospice the per diem payment for hospice services and acts as the primary payer for all care not related to the terminal condition; Medicaid pays the hospice at least 95% of the state's daily nursing home rate, and the hospice then pays the nursing home for the patient's room and board.
Per diem rates are adjusted using a wage index to account for differences in local wage costs. There is a cap on the total number of inpatient days that a hospice may provide services (20% of total days) and an annual aggregate cap on total Medicare hospice payments (for the fiscal year ending October 2007, this cap was $21,410.04 multiplied by the number of Medicare hospice patients enrolled during the year), but few hospices exceed the cap (OIG 1997) .
Hospice per diems have never been rebased.
3 Instead, per diems have been updated using either the increase in prices for the hospital market basket, the hospital market basket less some percentage, or a fixed percentage. Payers other than Medicare (including Medicaid) typically mirror the Medicare per diem methodology, although some commercial plans carve out certain high-cost services, such as specific pharmaceuticals, oral/enteral nutrition, and palliative chemotherapy, from the per diem and pay for them separately (Huskamp et al. 2001) . More details on the Medicare hospice payment methodology are available at this Web site: http://www.medpac.gov/documents/MedPAC_ Payment_Basics_07_hospice.pdf.
Study Population and Methods
We studied the 1,209 individuals over age 18 who used the study hospice from April 1, 2001 , through March 31, 2003 . The hospice is not-for-profit and located in the Northeast region. Using these patient-level data, we employed regression analysis to examine the association between patient characteristics and two types of dependent variables: the length of the hospice stay and hospice care costs. To understand whether the associations between patient characteristics and costs differed by type of hospice cost, we estimated models of total hospice costs as well as models of selected subcategories of costs (e.g., DME costs, medication costs).
The hospice, formerly a community hospice, is now a subsidiary of a cancer hospital and provides hospice services to individuals (with or without cancer) residing in their home or in a nursing facility (the hospice does not maintain an inpatient hospice facility for full-time inpatient hospice care). The hospice employs nurses, aides, social workers, and pastoral counselors, but contracts for additional nursing and aide services when its staff is unable to meet patient demand. The hospice also contracts with local vendors for items such as pharmacy, DME, medical supplies, oxygen, and physical therapy services.
We obtained information for each patient on all hospice services used, as well as demographics (age, gender), terminal diagnosis, marital status, insurance type, relationship of primary caregiver to patient, source of referral to hospice, and whether the individual resided in a nursing home during the hospice stay. The data include the total number of visits each patient received, but do not include service dates. Costs for services provided by staff were calculated as the average hourly wage rate for a particular type of staff member (e.g., nurse) multiplied by the number of hours of service provided. Transaction prices were used for all contracted services (i.e., additional nurse or aide services plus items like pharmacy, equipment, supplies, and physical therapy). Total costs for each patient include costs for staff services and contracted services as well as transportation (mileage multiplied by per mile reimbursement rate) and staff time spent screening and admitting the patient. Average costs per day equal the patient's total costs divided by the number of days in the hospice stay.
Our data are limited because certain types of costs (e.g., administrative overhead, bereavement services for family members of hospice patients) were not attributed to individual patients, so we cannot address the issue of the overall adequacy of payment levels. Although the distribution of patient characteristics in the studied hospice is similar to the national distribution in many respects, there are some differences. Compared to all hospice discharges in 2000 (using data from the National Home and Hospice Care Survey [NHHCS]), our sample has a higher proportion of cancer patients (69% versus 58% in the NHHCS), female patients (59% versus 50%), and unmarried or widowed patients (60% versus 53%), and a slightly lower proportion of patients with Medicare as the primary payer (75% versus 79%) (NCHS 2003) . Because only 31% of the patients in our sample have terminal diagnoses other than cancer and there is a broad range of noncancer diagnoses represented, we are unable to examine the association between specific noncancer diagnoses and costs.
Although our cost data are specific to the patient, they are not specific to the patient day; that is, we only observe cost for the entire stay. As a result, we cannot directly examine whether the costs of the first and last days of a stay are higher than the middle days of a stay, although we can implement an indirect test. Finally, because we studied only one urban hospice, we could not look at the issue of whether hospice costs are higher for rural hospices.
We estimated multivariate regression models of duration of the stay (measured in days), controlling for: age (18 to 54, 55 to 64, 65 to 74, and 85 years or older, with 75 to 84 as the reference category), gender, cancer diagnosis, marital status, caregiver type (child, relative, or other, with spouse as the reference category), primary insurer (private insurance or Medicaid/other, with Medicare as the reference category; dual-eligible patients are included with the Medicare group), 4 referral source (hospital, nursing home, visiting nurse association, or other, with physician/clinic as the reference category), whether the individual was a nursing home resident during the hospice stay, and whether the individual used any inpatient hospital care during the stay. In addition, from census data we include quartiles for the proportion of nonwhite residents and for median household income in the zip code of residence, as well as a dummy variable indicating whether census data were available for a particular patient (census data were unavailable for 37 patients). We were interested in estimating the relative magnitude of the association of each of these factors with duration of the stay. Since durations are skewed, we used the natural logarithm of days in the stay as our dependent variable.
We also estimated regression models for total cost of the entire hospice stay, average total costs per day, average total personnel (nurse, aide, social worker, and pastoral counselor) costs per day, average DME costs per day, and average pharmacy costs per day. Again, since costs are skewed, we used the natural logarithm of costs as our dependent variable. As noted earlier, we examined average costs per day (created by dividing total costs per patient by the number of days in the stay) because our data did not include a daily record of costs incurred for each patient. We estimated separate models of costs per day associated with each type of hospice personnel; because the results were similar across models, we aggregated personnel costs into a single category.
The cost models control for the same variables listed previously as well as the duration of stay categories (four to seven days, eight to 14, 15 to 30, 31 to 60, or over 60, with one to three days as the reference category). For 125 patients whose hospice stay started before or ended after the hospice's fiscal year (2001-2002 or 2002-2003) , we did not have cost information for days outside the fiscal year. Therefore, we included a dummy variable indicating whether the episode was censored. We also estimated the incremental R 2 to understand the incremental variation in total costs and costs per day explained by each of the categories of variables. We used a parametric retransformation to change the logarithm of cost to dollar cost, 5 and we present the adjusted estimated percentage change in costs for each variable.
Results
Most hospice users were 75 or older (55%), 59% were female, 69% had a terminal diagnosis of cancer, 60% were unmarried or widowed, and 72% had a spouse or child caregiver (Table 1) . Three-quarters (75%) had Medicare as the primary payer. Approximately one-third (38%) were referred by a hospital, one-fourth (25%) by a physician or clinic, and 13% by a nursing home. Fifteen percent resided in a nursing home during their hospice stay.
Among all hospice patients, 72% of patients used only routine home care days; seven patients used respite care, 16% used inpatient care, and 3% used continuous home care. Among those using any inpatient care, approximately two-thirds were in the hospital for their entire hospice stay.
Duration of Stays
Results from regression models of logged duration of stay suggest that men had shorter stays than women (Table 1) . Individuals with Medicaid or other insurance as the primary payer had longer stays than individuals with Medicare as the primary payer (including dual eligibles). Patients referred by a hospital had shorter stays than those referred by a physician or clinic, as did those referred by other sources (i.e., other than a hospital, nursing home, visiting nurse association, physician, or clinic). Those who received any general inpatient care (as opposed to inpatient care through the respite benefit) while enrolled in hospice had shorter stays than those who did not. There was no statistically significant difference in duration of stay for nursing home residents and nonresidents.
Costs
Nursing costs accounted for 29% of total costs, pharmacy for 21%, DME for 12%, aide costs for 6%, and social worker costs for 5% (Figure 1) . Overall, staffing accounted for 41% of all costs.
Total costs per stay. Mean total costs per stay were $2,192 (standard deviation [SD] 5$3, 199) , and the coefficient of variation for this variable was 1.46. Results from the regression model of logged total costs per stay suggest that such costs were generally higher among younger patients than among patients 75 to 84 (Table 2) . Controlling for duration of stay, total hospice costs per patient were substantially lower among nursing home residents than among nonresidents and higher among patients who used general inpatient care during their hospice stay relative to those who did not. Not surprisingly, total costs for the stay were higher for longer stays than for shorter stays.
Average total costs per day. Average total costs per day also were generally higher for younger patients relative to those 75 to 84 (Table 2 ). Similar to the pattern for total costs per stay, average total costs per day were substantially lower for nursing home residents than nonresidents, and higher for patients who used general inpatient care during their stay, relative to those who did not, controlling for duration of stay. Average total costs per day also decreased as duration of stay increased, consistent with the first and last days of a hospice stay being the most costly. Average personnel and DME costs per day. There were no significant differences in average personnel costs per day or DME costs per day on the basis of age, diagnosis, gender, marital status, caregiver type, or referral source (Table 3 ). Nursing home residents had lower average personnel costs per day and lower average DME costs per day than nonresidents, controlling for duration of stay. Patients who used general inpatient care during their hospice stay had lower average personnel costs per day than those who did not. As with average total costs per day, both personnel costs per day and DME costs per day decreased as duration of the stay increased.
Average pharmacy costs per day. Controlling for duration of stay, average pharmacy costs per day decreased with increasing age (Table 3) . Cancer patients had pharmacy costs per day that were 34% higher on average than non-cancer patients. Patients with Medicaid or other insurance as the primary payer had lower average pharmacy costs per day relative to Medicare patients, while patients referred by a hospital had 22% higher average pharmacy costs per day relative to patients referred by a physician or clinic. Nursing home residents had pharmacy costs per day that were 29% lower on average than nonresidents, and patients who used general inpatient care had 35% lower average pharmacy costs per day than patients who did not.
Understanding cost variation. Comparisons of the incremental measures of goodness-offit of the estimated models (i.e., the R 2 ) revealed that the duration of stay variables were, in fact, driving the total costs for the stay and the average total cost per day results ( Table 2 ). The R 2 s for the total cost models with all variables included were .65 for total costs for the entire stay, and .60 for average total cost per day. The incremental R 2 for duration of stay categories was .46 in the total cost model and .25 in the average total cost per day model. By contrast, the variables with the next highest incremental R 2 s were any use of general inpatient care (.10 for total cost and .14 for total cost per day) and nursing home residence (.03 for total cost and .05 for total cost per day).
To explore further the relationship between duration of stay and cost, we conducted two additional analyses: 1) a descriptive analysis of mean total costs per day by duration of stay, and 2) a multivariate regression model of logged average total costs per stay among Notes: Models include all variables in the table as well as quartiles for proportion of nonwhite residents and quartiles for median household income in the zip code of residence (from census data), and a variable indicating whether census data were available for a particular patient (census data were unavailable for 37 patients). The total cost variable excludes costs for inpatient hospital care and nursing home room and board because the hospice receives separate payment for these costs from Medicare and/or Medicaid. We retransformed from the logarithm of cost to dollar cost using a parametric retransformation. longer hospice stays (i.e., greater than two days). We find that mean total cost per day decreased dramatically as duration of stay increased. The mean cost per day for a oneday stay was $329 (n526), for a two-day stay was $251 (n573), and for a three-day stay was $204 (n5106). By contrast, the mean cost per day for stays of more than 120 days was $26 (n593). This finding is consistent with the GAO and 2006 MedPAC/Buntin report result that the mean number of visits (and thus hospice costs) is higher at the beginning and end of a hospice stay. For the multivariate model, we re-estimated the model of logged total costs for the entire hospice stay described earlier among stays of three or more days, replacing the duration of stay category variables with two other variables: 1) a variable that equals the number of days in the stay minus two; and 2) a variable that equals the square of the number of days minus two. 6 The coefficient on the number of days minus two variable reflects the incremental cost per day of each additional day in the middle of a stay (Table 4 ). The coefficient on the square of this variable indicates whether the relationship between number of days minus two and costs per stay is increasing or decreasing with the duration of the stay. We found a small, positive, and statistically significant effect on total costs for a hospice stay for each additional day beyond two days of enrollment. 7 The negative and significant coefficient on the square of the days minus two variable suggests that the cost of a hospice stay increases at a decreasing rate with longer stays.
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Conclusion and Policy Implications
This study of a single hospice permitted us to analyze detailed cost data of hospice users-data that have not been available until now-to examine variation in hospice costs. We found that the most important driver of average total costs per day of hospice care was the duration of the stay (with costs decreasing as duration increased). Our results suggest that average per day costs were markedly higher for stays of one or two days than for longer stays, and that total costs for longer stays increased at a decreasing rate as the length of stay increased. Average per day costs of hospice care were lower for nursing home residents than for nonresidents and higher for patients using general inpatient care during their hospice stay.
These results need to be replicated with detailed cost data from other hospices, ideally with costs that can be attributed to each day of the stay. But assuming these results prove to be robust, they suggest two alterations to Medicare payments for hospice, one of which has not been previously suggested.
Although we could not directly observe the costs of the first and last days of hospice stays using our data, our finding that costs per day are higher for one-and two-day stays than for longer stays suggests that per day costs are higher for the first days of the stay as the care team is becoming acquainted with the needs and preferences of the patient and the patient's family and a care plan is being created and implemented. Second, the decline in average cost per stay for stays of more than three days is consistent with higher costs at the end of the stay, which is consistent with knowledge of hospice care; that is, care becomes more intense and sometimes is provided around the clock as the patient nears death. Thus, our results provide empirical support for earlier calls for paying a higher Medicare reimbursement rate for these days (Huskamp et al. 2001 ).
9,10
Notes: Models include all variables in the table as well as quartiles for proportion of nonwhite residents and quartiles for median household income in the zip code of residence (from census data), and a variable indicating whether census data were available for a particular patient (census data were unavailable for 37 patients). We retransformed from the logarithm of cost to dollar cost using a parametric retransformation. a Personnel costs include costs incurred by the hospice for nurses, aides, LPNs, social workers and pastoral care. The personnel cost per day model excludes 31 patients for whom the hospice did not incur personnel costs after the admission process was complete. b The DME cost per day model excludes 458 patients for whom the hospice did not incur DME costs. c The pharmacy cost per day model excludes 168 patients for whom the hospice did not incur pharmacy costs.
Table 3. (continued)
Second, given that costs across the major cost categories were substantially lower for patients who lived in a nursing home during their hospice enrollment, the per diem for nursing home residents could be adjusted downward. On average, nursing home patients may be financially beneficial for the hospice under the current per diem system because nursing home residents may receive fewer hospice services than other patients due to potential overlap between services that nursing homes and hospices provide.
11 Also, provider travel costs per patient are likely to be lower if multiple patients come from a given nursing home (OIG 1997) . Any downward adjustment, however, needs to consider the possibility that hospices may experience a financial loss if the state Medicaid program pays less than 100% of the Medicaid reimbursement level for room and board instead of the full rate, leaving hospices responsible for the difference.
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Based on our findings and those from previous studies, CMS also should investigate an outlier payment system for patients with particularly high-cost palliative care needs. For example, hospice administrators reported that the high costs of certain new anti-cancer medications, such as Avastin, have resulted in hospice access problems for users of these medications. Avastin, which is sometimes used for palliative purposes in an attempt to shrink large tumors that are causing symptoms, costs approximately $4,000 to $5,000 a month, and the manufacturer plans to increase the price to $100,000 a year once its indications expand beyond colon cancer to include breast and lung cancer treatment (Berenson 2006) . Such high costs could exceed the entire hospice reimbursement for a patient. Unfortunately, we were unable to explore various outlier systems because our data come from a single hospice with a patient census that is insufficient for in-depth analysis of particularly high-cost patients (e.g., there are only 12 patients at the 99 th percentile of costs). Given a reasonably high coefficient of variation for total costs per stay in our data, a small hospice could face a substantial financial loss if it attracted even a few particularly high-cost cases at random in the absence of an outlier policy.
Costs also were substantially higher for patients who used general inpatient care during their hospice stay, although the hospice received a much higher per diem for inpatient days than for routine home (Greer et al. 1986 ). However, evidence of access problems for patients with particularly high-cost palliative care needs persists. Our results, in combination with those from the GAO and Buntin/MedPAC studies, provide important information on cost variation across patients and within a hospice stay. These studies suggest changes that could be made to the Medicare per diem payment system that potentially could reduce access problems and result in a closer match between costs incurred by hospices and the payments hospices receive. However, each of these studies focused on a single hospice, so the results are merely suggestive of patterns of costs across all hospices serving Medicare beneficiaries. As already noted, before making any adjustments to the per diem payment system, CMS should replicate the results of these studies in a broader, more representative sample of hospices.
1 Buntin imputed direct staffing costs using hospice visit data and Bureau of Labor Statistics wage data. 2 Hospices are permitted to charge 5% coinsurance for prescription drugs provided outside the inpatient setting, up to a maximum of $5 per drug. Many hospices, including the hospice studied in this analysis, do not charge patients this coinsurance. 3 Rebasing the Medicare hospice per diem payment system would involve selecting a new base year for assessing daily hospice costs. 4 Patients dually eligible for Medicare and Medicaid are classified as Medicare patients, since Medicare is the primary payer for these individuals. 5 We tested for constant variance and found that we could not reject that assumption. The retransformation from a lognormal distribution is exp(Xb + s 2 /2). Because we present relative differences, the constant variance term cancels out. 6 This specification is based on a total cost (TC) function TC 5 F + (n-2)X + L, where F is the cost of the first day of a stay, L is the cost of the last day of a stay, n is the number of days in the stay, and X is the average daily cost for days other than the first and last (i.e., the ''middle days'' of a stay). To examine how the incremental cost of each additional day of a stay changes with stay duration for longer stays (i.e., those exceeding two days), we use a quadratic total cost function to estimate total costs as a function of the number of days in the stay minus two (i.e., subtracting off the first and last days), the square of the number of days in the stay minus two, and an intercept term (which will capture the extra costs associated with the first and last days of these longer stays), in addition to the standard demographic and socioeconomic variables we include in all models. 7 The maximum of the total cost function occurs for stays of 702 days. In our sample, 1,206 observations involve stays of 557 or fewer days; only three stays lasted more than 702 days. 8 In examining incremental measures of the goodness-of-fit for the model in Table 4 , we found that total costs for the entire stay were driven primarily by duration of stay and inpatient use among stays of three or more days. The overall R 2 for the model was .50, and the incremental R 2 was .29 for the duration of stay variables and .11 for the inpatient use variable. 9 The Medicare inpatient prospective payment system does not use death to adjust payment (with the exception of acute myocardial infarction) to avoid the appearance of a death bonus. We doubt that that is an issue here, since all hospice patients are terminal. 10 Costs actually may be higher for the first two or three days and the last two or three days, rather than just the first and last. Additional research using data with a daily record of patient costs is needed to determine whether a payment adjustment for days at the beginning and end of a stay should apply to just the first (last) day or first few (last few) days.
11 Having nursing home residents with a terminal condition enrolled in hospice may also be financially beneficial for the nursing home. Nursing homes receive the same payment for a terminally ill patient enrolled in hospice as for a terminally ill patient who is not enrolled; this occurs even though the nursing home may incur lower costs in caring for a hospice patient since hospice personnel may be providing some services that the nursing home staff would have provided if the patient were not in hospice. 12 Although Medicaid pays hospices 95% of the Medicaid nursing home room and board rate, there is anecdotal evidence that some nursing homes require hospice to pay 100% of this rate, resulting in a financial loss for the hospice (see Tilly and Wiener 2001) . 13 Although the for-profit chains studied by GAO and Buntin (possibly the same chain) provide services to more hospice patients than the hospice we studied, the for-profit chains make key management decisions and set many clinical and purchasing policies centrally. Thus, in many respects, the data from each of these studies come from a single hospice organization as well.
